Barely Significant
← all excerpts

Dynamic ctDNA tracking stratifies relapse risk for triple negative breast cancer patients receiving neoadjuvant chemotherapy.

Nat Commun · 2025 · PMC11928511 · PMID 40118933

Europe PMCDOI
1
hedged sentence
0.2100
closest p · 4.2× alpha
0.2100
boldest claim

The sentences

showed a trendp = 0.21not close (p > 0.1)
The patients with positive baseline ctDNA showed a trend of worse EFS (Fig. 3A , p = 0.21, HR = 3.39, 95% CI: 0.44–26.3) and DRFS (Fig. 3B , p = 0.08, HR not calculable) than the ones with negative baseline ctDNA, but the differences were not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.